Market: NMS |
Currency: USD
Address: Building F
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Show more
📈 Outlook Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$4.83
-
Upside/Downside from Analyst Target:
860.90%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-14
-
EPS Estimate:
-0.12
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Outlook Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-14 (estimated upcoming) | - |
| 2026-02-17 | -0.22 |
| 2025-12-19 | -0.29 |
| 2025-08-14 | -0.44 |
| 2025-05-15 | -0.34 |
| 2025-02-14 | 0.72 |
| 2024-12-27 | -0.94 |
| 2024-08-14 | -0.83 |
| 2024-05-15 | -1.55 |
| 2024-02-14 | -0.78 |
| 2023-12-22 | -0.94 |
| 2023-08-14 | -1.38 |
| 2023-05-15 | -0.52 |
| 2023-02-14 | -1.59 |
| 2022-12-29 | -1.29 |
| 2022-08-10 | -1.56 |
| 2022-05-13 | -1.77 |
| 2022-02-14 | -1.41 |
| 2021-12-22 | -1.6 |
| 2021-08-13 | -1.4 |
| 2021-05-14 | -1.8 |
| 2021-02-16 | -2.2 |
| 2020-12-23 | -0.51 |
| 2020-08-14 | -2.2 |
| 2020-05-15 | -2.6 |
📰 Related News & Research
🔍 View more Reports
